Head-to-head · WeighScore
Sesame Care vs Zealthy
The verdict
Sesame Care takes it — 87.8/100 to 46.7/100.
Sesame Care grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. An established national telehealth marketplace with the widest real brand-name GLP-1 access on the board — Wegovy (pen and pill), Zepbound, Ozempic and Mounjaro — plus provider-by-provider price transparency.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Sesame Care | Zealthy |
|---|---|---|
| WeighScore | 87.8/100 | 46.7/100 |
| Grade | B+ | C |
| Scorecard rank | #2 | #496 |
| Semaglutide | From $149/mo (brand Wegovy pill) | $286/mo (starting dose, plus a separate fee, compounded) |
| Tirzepatide | Brand Zepbound (price varies) | $351/mo (starting dose, plus a separate fee, compounded) |
| Coverage | Nationwide marketplace | 34 states |
| Brand-name access | Yes | Compounded only |
| Oral / sublingual | Yes | Injection only |
Graded #2 · B+
Strengths
- Real FDA-approved brand-name access — Wegovy pen and pill, Zepbound, Ozempic, Mounjaro and Rybelsus
- Established platform (operating since 2018) with LegitScript, BBB accreditation and large third-party review volume
- You choose the provider and see the price up front — genuine marketplace transparency
- Oral routes available (Wegovy pill, Rybelsus)
Where it loses points
- A generalist marketplace, not a dedicated weight-loss program — lighter ongoing hand-holding than a specialist desk
- Two-part cost (a platform subscription plus the medication) makes the true monthly total harder to compare
- Brand-name cash prices can run high without insurance
Graded #496 · C
Strengths
- Serves 34 states — meaningful nationwide footprint
- Asynchronous model removes friction for patients who don't want a video visit
- Independent licensed prescribers retain full clinical authority
Where it loses points
- Active Novo Nordisk false-advertising lawsuit alleging trademark infringement and marketing compounded drugs as FDA-approved alternatives
- Active DOJ/FTC enforcement alleging undisclosed subscription terms, locked cancellation, and unauthorized health-data sharing
- Founder previously ran Cerebral, which settled with the FTC in 2024 over similar deceptive practices
- Recently rebranded to Gronk Inc. amid active enforcement
- FDA issued this company a warning letter dated 1 September 2025; the letter is public in FDA's warning-letter database
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.